|
Status |
Public on Aug 18, 2015 |
Title |
a phase 2 trial of DDMVAC and bevacizumab in urothelial cancer |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
A prognostic gene expression signature in chemotherapy-naïve bladder cancer is predictive of clinical outcomes from neoadjuvant chemotherapy
|
|
|
Overall design |
61 FFPE bladder tumors were used to validate chemo-resistant subtype in bladder cancer
|
|
|
Contributor(s) |
Choi W, Lee I, Siefker-Radtke A, McConkey D |
Citation(s) |
26343003 |
|
Submission date |
Jun 11, 2015 |
Last update date |
Jul 03, 2019 |
Contact name |
Woonyoung Choi |
Organization name |
Md Anderson Cancer center
|
Street address |
1515 Holcombe
|
City |
Houston |
State/province |
TX |
ZIP/Postal code |
77030 |
Country |
USA |
|
|
Platforms (1) |
GPL14951 |
Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip |
|
Samples (61)
|
|
Relations |
BioProject |
PRJNA286784 |